文献速递眼底病与葡萄膜炎

糖皮质激素联合或不联合传统改善病情抗风湿药作为非前葡萄膜炎型结节病性葡萄膜炎一线治疗

Corticosteroids with or without Conventional Disease-Modifying Antirheumatic Drug as First-Line Therapy in Nonanterior Sarcoidosis Uveitis.
PubMed 文献 · Ophthalmology · 2025-06-06

这项多中心回顾性研究纳入163例非前葡萄膜炎型结节病相关葡萄膜炎患者,比较单用全身糖皮质激素(CTC组122例)与糖皮质激素联合传统改善病情抗风湿药(CTC-DMARD组41例)的一线治疗效果。CTC-DMARD组12个月无治疗失败生存率(0.83,95%CI 0.67-0.91)高于CTC组(0.65,95%CI 0.55-0.72),校正多灶性脉络膜炎和基线糖皮质激素剂量后,CTC-DMARD组无治疗失败生存率显著更高(HR 2.21,95%CI 1.18-4.14,P=0.01)。作者认为CTC-DMARD似乎比CTC更有效,且安全性可接受。

要点

  • 12个月无治疗失败生存率CTC-DMARD组0.83 vs CTC组0.65。
  • 校正多灶性脉络膜炎和基线激素剂量后,CTC-DMARD组无治疗失败生存率显著更高(HR 2.21,95%CI 1.18-4.14,P=0.01)。
  • CTC-DMARD组在3个月和6个月时显示出显著减少激素用量的效应(P<0.05)。

核心结论

  • 在非前葡萄膜炎型结节病相关葡萄膜炎中,CTC-DMARD似乎比CTC更有效,且安全性可接受。

研究设计与样本

  • 多中心回顾性研究,纳入163例非前葡萄膜炎型结节病相关葡萄膜炎患者。
  • 比较一线全身糖皮质激素单用(CTC组,n=122)与糖皮质激素联合传统改善病情抗风湿药(CTC-DMARD组,n=41)。

主要发现

  • 12个月无治疗失败生存率CTC-DMARD组为0.83(95%CI 0.67-0.91),CTC组为0.65(95%CI 0.55-0.72)。
  • 校正多灶性脉络膜炎和基线糖皮质激素剂量后,CTC-DMARD组无治疗失败生存率显著高于CTC组(HR 2.21,95%CI 1.18-4.14,P=0.01)。
  • CTC-DMARD组在3个月和6个月时相比CTC组显示出显著减少激素用量的效应(P<0.05)。
  • CTC-DMARD组14例(34%)和CTC组50例(41%)发生至少1次不良事件。

临床怎么用

  • 作者认为,在非前葡萄膜炎型结节病相关葡萄膜炎中,CTC-DMARD似乎比CTC更有效,且安全性可接受。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Sarcoidosis is one of the leading causes of noninfectious uveitis. Systemic immunosuppressive treatment is required in 45% to 70% of patients for severe intermediate or posterior uveitis, and relapses are frequent (30%-60%) during follow-up. We aimed to compare the efficacy and safety of systemic corticosteroid therapy alone versus corticosteroid plus conventional disease-modifying antirheumatic drugs (C-DMARDs) as first-line therapy in patients with nonanterior sarcoidosis uveitis. DESIGN: We conducted a multicenter, retrospective study. PARTICIPANTS: One hundred sixty-three patients with nonanterior sarcoidosis-related uveitis were included. METHODS: We compared first-line therapy with systemic corticosteroids alone (CTC; n = 122) versus corticosteroids plus C-DMARDs (CTC-DMARD; n = 41). MAIN OUTCOME MEASURES: The primary outcome was treatment failure-free survival (TFFS) defined by the discontinuation of treatment for inefficiency or the occurrence of relapse. RESULTS: Treatment failure-free survival at 12 months was 0.83 (95% confidence interval [CI], 0.67-0.91) and 0.65 (95% CI, 0.55-0.72), respectively, in the CTC-DMARD and CTC groups. In multivariable analysis adjusted on multifocal choroiditis and baseline dose of corticosteroids, the TFFS was significantly higher in the CTC-DMARD group compared with the CTC group (hazard ratio, 2.21; 95% CI, 1.18-4.14; P = 0.01). A significant steroid-sparing effect at 3 and 6 months was noted (P < 0.05) in the CTC-DMARD group compared with the CTC group. Fourteen patients (34%) and 50 patients (41%) experienced at least 1 adverse event in the CTC-DMARD and CTC groups, respectively. CONCLUSIONS: In nonanterior sarcoidosis-associated uveitis, the CTC-DMARD seemed to be more efficient than CTC, with an acceptable safety profile. FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Jacquot R, Sève P, Mulier G, et al. Corticosteroids with or without Conventional Disease-Modifying Antirheumatic Drug as First-Line Therapy in Nonanterior Sarcoidosis Uveitis. Ophthalmology. 2025. PMID: 40484138. doi:10.1016/j.ophtha.2025.05.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。